Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Vandemeulebroecke

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Biometrical Journal. Biometrische Zeitschrift|July 30, 2008
Group sequential and adaptive designs - a review of basic concepts and points of discussionMarc Vandemeulebroecke
Biometrical Journal. Biometrische Zeitschrift|September 16, 2006
A brief review on software developments for group sequential and adaptive designsGernot Wassmer, Marc Vandemeulebroecke
Pharmaceutical Statistics|June 7, 2016
A modified varying-stage adaptive phase II/III clinical trial designGaohong Dong, Marc Vandemeulebroecke
Statistics in Medicine|April 16, 2021
Win odds: An adaptation of the win ratio to include tiesEdgar Brunner, Marc Vandemeulebroecke, Tobias Mütze
Clinical Pharmacology and Therapeutics|December 23, 2021
Innovative Pediatric Development for Secukinumab in Psoriasis: Faster Patient Access, Reduction of Patients on ControlRuquan You, Sebastian Weber, Bruno Bieth, et al.
Trials|April 21, 2023
DMC reports in the 21st century: towards better tools for decision-makingMarc Vandemeulebroecke, Mark Baillie, Ardalan Mirshani, et al.
Journal of Biopharmaceutical Statistics|November 28, 2017
The stratified win ratioGaohong Dong, Junshan Qiu, Duolao Wang, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 23, 2019
Effective Visual Communication for the Quantitative ScientistMarc Vandemeulebroecke, Mark Baillie, Alison Margolskee, et al.
Pharmaceutical Statistics|August 4, 2016
A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among componentsGaohong Dong, Di Li, Steffen Ballerstedt, et al.
Pharmaceutical Statistics|June 4, 2014
When is a seamless study desirable? Case studies from different pharmaceutical sponsorsRobert L Cuffe, David Lawrence, Andrew Stone, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Biometrical Journal. Biometrische Zeitschrift|July 30, 2008
Group sequential and adaptive designs - a review of basic concepts and points of discussionMarc Vandemeulebroecke
Biometrical Journal. Biometrische Zeitschrift|September 16, 2006
A brief review on software developments for group sequential and adaptive designsGernot Wassmer, Marc Vandemeulebroecke
Pharmaceutical Statistics|June 7, 2016
A modified varying-stage adaptive phase II/III clinical trial designGaohong Dong, Marc Vandemeulebroecke
Statistics in Medicine|April 16, 2021
Win odds: An adaptation of the win ratio to include tiesEdgar Brunner, Marc Vandemeulebroecke, Tobias Mütze
Clinical Pharmacology and Therapeutics|December 23, 2021
Innovative Pediatric Development for Secukinumab in Psoriasis: Faster Patient Access, Reduction of Patients on ControlRuquan You, Sebastian Weber, Bruno Bieth, et al.
Trials|April 21, 2023
DMC reports in the 21st century: towards better tools for decision-makingMarc Vandemeulebroecke, Mark Baillie, Ardalan Mirshani, et al.
Journal of Biopharmaceutical Statistics|November 28, 2017
The stratified win ratioGaohong Dong, Junshan Qiu, Duolao Wang, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 23, 2019
Effective Visual Communication for the Quantitative ScientistMarc Vandemeulebroecke, Mark Baillie, Alison Margolskee, et al.
Pharmaceutical Statistics|August 4, 2016
A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among componentsGaohong Dong, Di Li, Steffen Ballerstedt, et al.
Pharmaceutical Statistics|June 4, 2014
When is a seamless study desirable? Case studies from different pharmaceutical sponsorsRobert L Cuffe, David Lawrence, Andrew Stone, et al.
Pageof 4